事件：近日，礼来发布2025 年第一季度财报。（来源：礼来，太平洋证券研究院）核心观点：GLP-1 药物驱动核心业绩，2025Q1 收入增长强劲。礼来2025Q1 总营收127.29 亿美元，同比增长45%，主要受益于替尔泊肽的的强劲销售。替尔泊肽合计贡献61.5 亿美元的收入，占2025Q1 的比重约48%，其中Mounjaro（糖尿病适应症）全球收入为38.4 亿美元（同比+113%），...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.